Jibiki, Aya

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 医療薬学・社会連携センター 医療薬学部門 (Shiba-Kyoritsu)

Position

Research Associate/Assistant Professor/Instructor

Career 【 Display / hide

  • 2005.04
    -
    2014.07

    University of Tsukuba Hospital, Department of Pharmacy, Chief

  • 2014.08
    -
    Present

    Keio University, Faculty of Pharmacy, Division of Pharmaceutical Care Sciences, Research Associate

Academic Background 【 Display / hide

  • 1999.04
    -
    2003.03

    Meiji Pharmaceutical University, 薬学部

    University, Graduated

  • 2003.04
    -
    2005.03

    Chiba University, 大学院薬学研究院

    Graduate School, Completed, Master's course

Licenses and Qualifications 【 Display / hide

  • Pharmacist license, 2003.06

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy

Research Keywords 【 Display / hide

  • proper use of steroids, connective tissue disease, menopausal syndrome, osteoporosis, bitter-taste masking of medicine

  • 更年期障害に対する薬物治療

  • Kampo Medicine

  • 膠原病

  • 医薬品の苦味マスキング

display all >>

Research Themes 【 Display / hide

  • 更年期障害に対する漢方製剤処方実態調査および漢方治療不応例の要因分析, 

    2018.02
    -
    2021.03

     View Summary

    更年期障害の女性に対する漢方製剤処方実態調査を行うとともに、漢方治療の不応例についてその要因を分析し、更年期障害に対する漢方製剤を中心とした薬物治療の最適化、個別化につなげていく

  • グルココルチコイド(GC)使用膠原病患者におけるGC誘発性糖尿病に対する処方実態調査および治療薬の有用性の検討, 

    2017.12
    -
    2020.03

     View Summary

    GC製剤を使用している膠原病患者において、糖尿病(GC誘発性糖尿病)の発現状況、GC誘発性糖尿病に対する治療薬の処方実態や臨床検査値等について調査し、各種糖尿病治療薬のGC誘発性糖尿病に対する有用性について検討する。

 

Books 【 Display / hide

  • こどもと薬のQ&A続

    石川洋一 監修 小児薬物療法研究会 編集(編集協力者:地引 綾), じほう, 2018.09

Papers 【 Display / hide

  • Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E)

    Namiki T., Yokoyama Y., Hashi H., Oda R., Jibiki A., Kawazoe H., Matsumoto K., Suzuki S., Nakamura T.

    Pharmacotherapy (Pharmacotherapy)   2023.11

    ISSN  02770008

     View Summary

    Study Objective: Establish methods for measuring cefmetazole (CMZ) concentrations conduct a pharmacokinetic/pharmacodynamic (PK/PD) analysis using unbound CMZ concentrations for extended-spectrum β-lactamase producing enterobacterales (ESBL-E) and investigate optimal dosing regimens for not undergoing hemodialysis (non-HD) and undergoing hemodialysis (HD) patients. Design: Prospective observational study. Patients: Included patients treated with CMZ who provided written informed consent and were admitted to the Tokyo Bay Urayasu Ichikawa Medical Center between August 2021 and July 2022. Measurements: Total and Unbound CMZ concentration was measured by high-performance liquid chromatography (HPLC) with solid-phase extraction and ultrafiltration. Setting: Determining the CMZ dosing regimen involved modified creatinine clearance (CLCR) with measured body weight (BW) using the Cockcroft–Gault equation. For non-HD patients, blood samples were collected during at least three points. For patients undergoing HD, 1 g was administered via intravenous infusion, or rapid intravenous injection after HD, or 30 min before the end of HD. Blood samples were collected before HD (pre-HD), and 1 and 3 h after starting HD and post-HD. All blood samples were collected at steady-state. Patient information was collected from electronic medical records. An unbound PK model was constructed for the non-HD patients. A nomogram was constructed using Monte Carlo simulations with a 90% probability of target attainment at 70% free time above the minimum inhibitory concentration (MIC). For the HD patients, a nomogram was used to determine the optimal dosing regimen for each HD schedule. Main Results: CMZ measurement methods were established. A model analysis of unbound PK in 37 non-HD patients incorporated creatinine clearance (CLCR) using the Cockcroft–Gault equation, albumin (ALB) for clearance and body weight (BW) for the volume of distribution. In Monte Carlo simulations, nomograms corresponding to the MIC (known and unknown) were generated for each covariate. Using the nomogram, non-HD patients with an ESBL-E MIC of 8 mg/L, a BW of 60 kg, an ALB of 25 g/L, and a CLCR of 60 mL/min required administration of 2 g every 6 h (1- and 3-h infusions). Unbound PK model parameters were calculated for 7 HD patients, and the optimal dosing regimens following PK/PD were determined for each HD schedule. In HD patients, the regimen after and during HD was established using a treatment that was effective up to an ESBL-E MIC of 4 mg/L. Conclusions: The nomogram for CMZ regimens established by PK/PD analysis of measured CMZ concentrations enables optimal CMZ dosing for ESBL-E-infected patients.

  • What factors improve the evaluation of achievement at the end of pharmacy practice experiences?

    石川春樹, 河添 仁, 岩田紘樹, 中村友紀, 地引 綾, 横山雄太, 小林典子, 鈴木小夜, 山浦克典, 中村智徳

    医療薬学 (一般社団法人 日本医療薬学会)  49 ( 4 ) 173 - 182 2023.04

    Research paper (scientific journal), Joint Work, Accepted

  • Ingenol mebutate inhibits the growth of pancreatic cancer cells in vitro via STING with an efficacy comparable to that of clinically used anticancer agents

    Fumihiro Kikuyama, Sayo Suzuki, Aya Jibiki, Yuta Yokoyama, Hitoshi Kawazoe, Susumu Kitanaka, Tomonori Nakamura

    Journal of Natural Medicines (Journal of Natural Medicines)  77 ( 2 ) 343 - 351 2023.01

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  13403443

     View Summary

    Pancreatic cancer is associated with a poor prognosis; thus, there is an urgent need to develop new and effective treatments. Ingenol mebutate (IM), which is isolated from the latex of Euphorbia peplus, was recently shown to be effective against pancreatic cancer cell lines; however, its mechanism of action has not been fully elucidated. In this study, we focused on the less drug-sensitive pancreatic cancer cell line Panc-1 and compared IM to commercially available anticancer drugs using cell survival assays. In addition, we aimed to identify novel biomolecules that may be involved in the mechanism of action of IM using RNA sequencing, western blotting, and inhibition assays. The IC50 values after 72 h of exposure to IM and SN-38, drugs to which the Panc-1 cells are most sensitive among the tested anticancer agents, were 43.1 ± 16.8 nM and 165 ± 37 nM, respectively. IM showed a cytostatic effect equal to or greater than that of the clinically used pancreatic cancer therapeutic drugs. RNA sequencing and protein expression analysis revealed that expression of stimulator of interferon genes (STING) increased at low IM concentration, whereas cell viability decreased. Co-exposure of IM and STING inhibitor, H-151, to Panc-1 or MIA PaCa-2 cell lines canceled the growth-inhibitory effects of IM alone. In conclusion, IM may have an efficacy comparable to that of existing pancreatic cancer therapeutic agents on the less drug-sensitive Panc-1 cell line and the immune-related molecule STING plays a role in the mechanism of action of IM.

  • Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small-cell Lung Cancer: a Prospective Observational Study

    Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura

    Investigational New Drugs (Investigational New Drugs)  41 ( 1 ) 122 - 133 2023.01

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  01676997

     View Summary

    Background: Potential novel strategies for adverse event (AE) management of osimertinib therapy, including therapeutic drug monitoring and the use of biomarkers, have not yet been fully investigated. This study aimed to evaluate (1) the relationship between exposure to osimertinib, especially its active metabolites (AZ5104 and AZ7550), and AEs, and (2) the relationship between germline polymorphisms and AEs. Methods: We conducted a prospective, longitudinal observational study of 53 patients with advanced non-small cell lung cancer receiving osimertinib therapy from February 2019 to April 2022. A population pharmacokinetic model was developed to estimate the area under the serum concentration–time curve from 0 to 24 h (AUC0–24) of osimertinib and its metabolites. Germline polymorphisms were analyzed using TaqMan® SNP genotyping and CycleavePCR® assays. Results: There was a significant association between the AUC0–24 of AZ7550 and grade ≥ 2 paronychia (p = 0.043) or anorexia (p = 0.011) and between that of osimertinib or AZ5104 and grade ≥ 2 diarrhea (p = 0.026 and p = 0.049, respectively). Furthermore, the AUC0–24 of AZ5104 was significantly associated with any grade ≥ 2 AEs (p = 0.046). EGFR rs2293348 and rs4947492 were associated with severe AEs (p = 0.019 and p = 0.050, respectively), and ABCG2 rs2231137 and ABCB1 rs1128503 were associated with grade ≥ 2 AEs (p = 0.008 and p = 0.038, respectively). Conclusion: Higher exposures to osimertinib, AZ5104, and AZ7550 and polymorphisms in EGFR, ABCG2, and ABCB1 were related to higher severity of AEs; therefore, monitoring these may be beneficial for osimertinib AE management.

  • Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography–Photodiode array detection

    Yokoyama Y., Nozawa E., Morita M., Ishikawa E., Mori T., Sakurai M., Kikuchi T., Matsuki E., Yamazaki R., Kataoka K., Jibiki A., Kawazoe H., Suzuki S., Nakamura T.

    Journal of Clinical Laboratory Analysis (Journal of Clinical Laboratory Analysis)  36 ( 8 )  2022.08

    ISSN  08878013

     View Summary

    Background: Dasatinib, nilotinib, and bosutinib, second-generation tyrosine kinase inhibitors (TKIs), and ponatinib, a third-generation TKI, are approved pharmaceuticals used in the treatment of chronic myeloid leukemia (CML). Although liquid chromatography-tandem mass spectrometry assays for simultaneous quantification of the four TKIs in human serum have been reported in the literature, a high-performance liquid chromatography (HPLC) assay that simultaneously quantifies these compounds has not yet been developed. This study aims to establish and validate an efficient HPLC analytical method using a photodiode array (PDA) detector for the simultaneous quantification of the four TKIs. Methods: Calibration standards were prepared by serial dilution of serum samples containing the four TKIs, followed by solid-phase extraction. The four TKIs were eluted in order within 10 min using a binary HPLC gradient system. Results: The calibration ranges were 2–500 ng/ml for dasatinib, 100–5000 ng/ml for nilotinib, and 10–500 ng/ml for bosutinib and ponatinib. Intra-day and inter-day precision and accuracy values were found to be in accordance with the U.S. Food and Drug Administration guidelines. The recovery rates were 92.9%–96.0%, 80.7%–86.1%, 91.6%–99.0%, and 86.4%–92.6% for dasatinib, nilotinib, bosutinib, and ponatinib, respectively. Conclusion: To the best of our knowledge, this is the first report of an HPLC-PDA analytical method that allows efficient simultaneous quantification of the four TKIs in the serum of patients with CML. We believe that the method developed herein can improve the efficiency of therapeutic drug monitoring in patients with CML in clinical practice.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • がん薬物治療における職業性暴露対策の新たな動きと未来展望

    Hitoshi Kawazoe, Sayo Suzuki, Yuta Yokoyama, Aya Jibiki, Tomonori Nakamura

    Japanese Journal of Drug Safety 5 ( 2 ) 67 - 76 2019.12

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Steroids as cancer medication

    Aya Jibiki, Yuta Yokoyama, Hitoshi Kawazoe, Sayo Suzuki, Tomonori Nakamura

    Japanese Journal of Drug Safety 5 ( 1 ) 1 - 13 2019.06

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Consideration of cancer treatments and clinical trials for special patient populations

    Sayo Suzuki, Jibiki Aya,Yuta Yokoyama, Hitoshi Kawazoe, Tomonori Nakamura

    Japanese Society of Drug Safety (Japanese Society of Drug Safety)  4 ( 2 ) 83 - 97 2018.12

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Toward routine therapeutic drug monitoring of the epidermal growth factor receptor-the tyrosine kinase inhibitors

    Yuta Yokoyama, Sayo Suzuki, Jibiki Aya,Hitoshi Kawazoe, Tomonori Nakamura

    Japanese Society of Drug Safety (Japanese Society of Drug Safety)  4 ( 1 ) 3 - 13 2018.07

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • クロピドグレルの効果に影響する因子は何か?

    ファルマシア (日本薬学会)  45 ( 11 ) 1142 - 1143 2009.11

    Article, review, commentary, editorial, etc. (other), Single Work

display all >>

Presentations 【 Display / hide

  • 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築

    並木 孝哉, 横山 雄太, 枦 秀樹, 織田 錬太郎, 地引 綾, 河添 仁, 松元 一明, 鈴木 小夜, 中村 智徳

    第44回日本臨床薬理学会学術総会 (神戸) , 

    2023.12

    Oral presentation (general), 一般社団法人 日本臨床薬理学会

  • 実務実習終了時における実習生の到達度評価を向上させる要因の検討

    石川春樹, 河添 仁, 岩田紘樹, 中村友紀, 地引 綾, 横山雄太, 小林典子, 鈴木小夜, 山浦克典, 中村智徳

    第33回日本医療薬学会年会 (宮城) , 

    2023.11

    Poster presentation, 一般社団法人 日本医療薬学会

  • Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: A Prospective Observational Study

    Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura

    The 21th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Norway) , 

    2023.09

    Oral presentation (general)

  • Investigating the effect of tacrolimus exposure on the acute rejection reaction after pediatric liver transplantation using population pharmacokinetic analysis

    Yuta Yokoyama, Momoka Murakami, Jumpei Saito, Aya Jibiki, Hitoshi Kawazoe, Akimasa Yamatani, Sayo Suzuki, Tomonori Nakamura

    The 21th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (Norway) , 

    2023.09

    Poster presentation

  • セフメタゾールに関連する国際標準比(INR)上昇のリスク因子特定と予測モデルの構築

    並木 孝哉, 横山 雄太, 木村 元範, 福田 正悟, 瀬山 翔史, 池谷 修, 佐村 優, 石川 春樹, 地引 綾, 河添 仁, 大谷 壽一, 長谷川 直樹, 松元 一明, 枦 秀樹, 鈴木 小夜, 中村 智徳

    第17回次世代を担う若手のための医療薬科学シンポジウム (長野) , 

    2023.09

    Oral presentation (general), 一般社団法人 日本薬学会

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 更年期障害患者に対する最適な治療薬選択を目指したエストロゲン受容体遺伝子解析

    2021.04
    -
    2022.03

    慶應義塾大学, 慶應義塾2021年度学事振興資金 研究補助, Aya Jibiki, Research grant, Principal investigator

  • グルココルチコイド誘発性糖尿病患者におけるインスリン離脱困難例の要因分析

    2019.04
    -
    2020.03

    慶應義塾大学, 慶應義塾2019年度学事振興資金 研究補助, Research grant, Principal investigator

  • Analysis of factors influencing failure of treatment with harbal medicine for menopausal symptoms

    2018.04
    -
    2021.03

    The Research Foundation for Pharmaceutical Sciences, JIBIKI Aya, Research grant, Principal investigator

  • グルココルチコイド誘発性糖尿病に対する薬物治療の洗練化と発症予測因子の検討

    2018.04
    -
    2020.03

    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research, JIBIKI AYA, Research grant, Principal investigator

     View Summary

    グルココルチコイド(GC)の副作用のうち、GC誘発性糖尿病に着目し、薬物治療の洗練化およびGC誘発性糖尿病の発症予測や早期発見を目指して以下の検討を行う。
    ①GC誘発性糖尿病患者の処方実態について調査し、各種糖尿病治療薬のGC誘発性糖尿病に対する有用性について検討する。
    ②GC内服患者の血中・尿中の11β-Hydroxysteroid dehydrogenase type 1(11β-HSD1)活性を測定し、GC誘発性糖尿病の発現
    群と非発現群において11β-HSD1活性に違いがあるかどうかを比較検討するとともに、11β-HSD1活性とインスリン抵抗性との間に相関があるかどうか検討し、発症予測や早期発見の指標として利用できるか否かを検証する。

Awards 【 Display / hide

  • Best Presentation Award

    Aya Jibiki, Saeko Murakami, Tetsuhiro Yoshino, Yuko Horiba, Yuta Yokoyama, Hitoshi Kawazoe, Sayo Suzuki, Kenji Watanabe, Tomonori Nakamura, 2023.02, The Japanese Association for Gender-Specific Medicine, 更年期症状に対する漢方治療不応例の分析

    Type of Award: Award from Japanese society, conference, symposium, etc.

 

Courses Taught 【 Display / hide

  • RESEARCH FOR BACHELOR'S THESIS 1

    2023

  • PRIOR LEARNING FOR CLINICAL PRACTICE 3

    2023

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2023

  • PRACTICAL LEARNING ON SUPPORTING THE HEALTH PROMOTION OF COMMUNITY

    2023

  • PHARMACY PRACTICE IN HOSPITAL & COMMUNITY PHARMACY

    2023

display all >>

Courses Previously Taught 【 Display / hide

  • 実務実習事前学習(実習)

    Keio University

    2018.04
    -
    2019.03

    Autumn Semester, Laboratory work/practical work/exercise, Outside own faculty (within Keio), 4h, 40people

  • 実務実習事前学習3

    Keio University

    2018.04
    -
    2019.03

    Autumn Semester, Lecture, Outside own faculty (within Keio), 160people

    緊急情報の扱い方

  • 実務実習の前に(6)

    Keio University

    2018.04
    -
    2019.03

    Spring Semester, Lecture, Outside own faculty (within Keio), 1h, 160people

  • Prior learning for clinical practice 3

    Keio University

    2017.04
    -
    2018.03

    Autumn Semester, Lecture, Outside own faculty (within Keio), 1h, 160people

    緊急情報の取り扱い

  • Preclinical practice (6)

    Keio University

    2017.04
    -
    2018.03

    Spring Semester, Lecture, Outside own faculty (within Keio), 1h, 152people

    治験薬管理

 

Memberships in Academic Societies 【 Display / hide

  • 日本女性医学会, 

    2023.04
    -
    Present
  • Japanese Society of Drug Safety, 

    2019
    -
    2023
  • Japan Society for Pharmaceutical Education, 

    2017
    -
    Present
  • 日本老年医学会, 

    2015.05
    -
    2021.03
  • 日本病院薬剤師会, 

    2015
    -
    Present

display all >>